1
|
Somani S, Takhar S, Miller D, Camarillo H, Zhu M, Tran K. Compass Rose™ Implementation in a Large Academic Medical Center. EXPLORATORY RESEARCH IN CLINICAL AND SOCIAL PHARMACY 2024; 15:100462. [PMID: 38983636 PMCID: PMC11231745 DOI: 10.1016/j.rcsop.2024.100462] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/22/2024] [Revised: 05/01/2024] [Accepted: 06/06/2024] [Indexed: 07/11/2024] Open
Abstract
Background Compass Rose™, a case management tool developed by Epic®, was designed to track various patient coordination tasks, outreaches, and outcomes. This report describes the implementation of Compass Rose™ within an internal health-system specialty pharmacy (HSSP) and changes in care coordination metrics before and after implementation. To the best of our knowledge, this is the first study of its kind to discuss the implementation of Compass Rose™. Objectives The goals of this study were to describe the implementation process of Compass Rose™ at an internal HSSP and compare staff satisfaction before and after Compass Rose™ as the primary outcome. Methods This was an Institutional Review Board exempt, retrospective cohort study conducted between June 2022 to December 2022 that assessed staff satisfaction, refill documentation time, prescription turnaround time, and patient satisfaction pre- and post- Compass Rose™ implementation through survey administration, observed time studies, and internal data reports. The process of Compass Rose™ implementation was also described and discussed. Results 24 specialty pharmacy staff members participated in the Compass Rose™ implementation survey. No statistically significant differences were observed in either staff satisfaction (3.96 ± 0.95 versus 3.70 ± 0.69, p = 0.29) or predicted versus actual challenge of implementation (3.67 ± 1.17 versus 3.09 ± 0.96, p = 0.064). There was no significant difference in refill documentation time pre- versus post- Compass Rose™ implementation (4.22 ± 3.15 minutes versus 4.10 ± 2.36 minutes, p = 0.82); however, there was a statistically significant increase in prescription turnaround time post implementation (2.59 ± 2.85 days versus 2.69 ± 2.35 days, p = 0.002). Conclusion Compass Rose™ implementation had no significant impact on staff satisfaction, patient satisfaction, or overall refill documentation time. Prescription turnaround time increased, which could be due to significant workflow changes with Compass Rose™ or several other contributing factors such as increased prescription volume and training new staff during this period.Benefits of Compass Rose™ included standardization of workflow, ability to quantify staff performance and clinical impact, and increased transparency regarding care provided by the specialty pharmacy team.
Collapse
Affiliation(s)
- Selina Somani
- University of California, Davis Health Department of Pharmacy, Sacramento, CA, United States of America
| | - Shannan Takhar
- University of California, Davis Health Department of Pharmacy, Sacramento, CA, United States of America
| | - Derek Miller
- University of California, Davis Health Department of Pharmacy, Sacramento, CA, United States of America
| | - Hana Camarillo
- University of California, Davis Health Department of Pharmacy, Sacramento, CA, United States of America
| | - Mency Zhu
- University of California, Davis Health Department of Pharmacy, Sacramento, CA, United States of America
| | - Kathie Tran
- University of California, Davis Health Department of Pharmacy, Sacramento, CA, United States of America
| |
Collapse
|
2
|
Patrawala S, Mustafa SS, Ramsey A. Role of an embedded health system specialty pharmacy on prescription of biologics in allergy/immunology. Ann Allergy Asthma Immunol 2024:S1081-1206(24)00432-0. [PMID: 39009218 DOI: 10.1016/j.anai.2024.07.012] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/29/2024] [Revised: 07/09/2024] [Accepted: 07/09/2024] [Indexed: 07/17/2024]
Affiliation(s)
- Sara Patrawala
- Rochester Regional Health, Rochester, New York; University of Rochester School of Medicine and Dentistry, Rochester, New York.
| | - S Shahzad Mustafa
- Rochester Regional Health, Rochester, New York; University of Rochester School of Medicine and Dentistry, Rochester, New York
| | - Allison Ramsey
- Rochester Regional Health, Rochester, New York; University of Rochester School of Medicine and Dentistry, Rochester, New York
| |
Collapse
|
3
|
Kelley TN, Canfield S, Diamantides E, Ryther AMK, Pedersen CA, Pierce G. ASHP Survey of Health-System Specialty Pharmacy Practice: Practice Models, Operations, and Workforce - 2022. Am J Health Syst Pharm 2023; 80:1796-1821. [PMID: 37742303 DOI: 10.1093/ajhp/zxad235] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/21/2023] [Indexed: 09/26/2023] Open
Abstract
PURPOSE The results of the 2022 American Society of Health-System Pharmacists (ASHP) Survey of Health-System Specialty Pharmacy (HSSP) Practice: Practice Models, Operations, and Workforce are presented. METHODS A total of 273 leaders in HSSPs were contacted by email to complete a survey hosted using Qualtrics. The survey sample was compiled from ASHP member lists, the presence of a specialty pharmacy indicated in previous ASHP surveys, and outreach to ASHP member organizational leaders. RESULTS The survey response rate was 35.9%. Most HSSPs dispense 30,000 or fewer specialty prescriptions annually. Most respondents have an annual revenue of $100 million or less, are part of a 340B-covered entity, operate one location, have 1 to 2 specialty pharmacy accreditations, dispense both nonspecialty and specialty medications, and employ an average of 15.5 pharmacists and 17.6 technicians. The majority (66.7%) dispense 50% or less of prescriptions written by internal providers due to payor and manufacturer network restrictions. Over one-third employ nonpharmacist and nontechnician professionals. Specialty pharmacists are involved in treatment decisions and therapy selection before prescription generation (69.8%), and 47.7% of respondents report pharmacists operating under collaborative practice agreements. Most (82.6%) offer experiential or formal education in specialty pharmacy. The top point of pride remains patient satisfaction and level of service. Top challenges include access to payor networks, the ability to hire and retain qualified staff, and shrinking reimbursement from payors. CONCLUSION The HSSP is a continually maturing integrated advanced practice model focused on providing patient-centric care to all patients and employees of the health system regardless of network status. HSSPs are raising the standards for quality in specialty pharmacy care.
Collapse
Affiliation(s)
- Tara N Kelley
- Vanderbilt Specialty Pharmacy Services, Nashville, TN, USA
| | - Scott Canfield
- Clinical Program Development, Johns Hopkins Home Care Group, Baltimore, MD, USA
| | | | | | - Craig A Pedersen
- Virginia Mason Franciscan Health, Seattle, WA, and University of Washington, Seattle, WA, USA
| | - Gabrielle Pierce
- Member Relations, Section of Specialty Pharmacy Practitioners, American Society of Health-System Pharmacists, Bethesda, MD, USA
| |
Collapse
|
4
|
Zuckerman AD, Mourani J, Smith A, Ortega M, Donovan JL, Gazda NP, Tong K, Simonson D, Kelley T, DeClercq J, Choi L, Pierce G. 2022 ASHP Survey of Health-System Specialty Pharmacy Practice: Clinical Services. Am J Health Syst Pharm 2023; 80:827-841. [PMID: 36999452 DOI: 10.1093/ajhp/zxad064] [Citation(s) in RCA: 4] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/24/2023] [Indexed: 04/01/2023] Open
Abstract
PURPOSE Results of the first ASHP national survey of clinical services provided by health-system specialty pharmacies (HSSPs) are presented. METHODS A survey questionnaire was developed by 26 HSSP contacts after reviewing available literature on the role and services of HSSPs. After pilot and cognitive testing resulting in a final questionnaire of 119 questions, a convenience sample of 441 leaders in HSSPs was contacted using email and invited to participate in the survey. RESULTS The survey response rate was 29%. Almost half of respondents (48%) had offered pharmacy services for 7 years or more, and most (60%) dispensed more than 15,000 prescriptions annually. Respondents most commonly (42%) reported a specialist model wherein staff are dedicated to specific specialty disease states. Over half of respondents reported providing several medication access, pretreatment assessment, and initial counseling services to patients referred to them, regardless of whether the HSSP was used for medication fulfillment. All HSSP activities were noted to be documented in the electronic health record and visible to providers frequently or always. Almost all respondents noted that HSSP pharmacists have a role in specialty medication selection. Disease-specific outcomes were tracked in 95% of responding HSSPs, with 67% reporting that outcomes were used to drive patient monitoring. HSSPs were often involved in continuity of care services such as transitions of care (reported by 89% of respondents), referral to other health-system services (53%), and addressing social determinants of health (60%). Most respondents (80%) reported providing clinical education to specialty clinic staff, including medicine learners (62%). Though only 12% of respondents had dedicated outcomes research staff, many reported annually publishing (47%) or presenting (61%) outcomes research. CONCLUSION HSSPs are a clinical and educational resource for specialty clinics and have developed robust patient care services that encompass the patient journey from before specialty medication selection through treatment monitoring and optimization.
Collapse
Affiliation(s)
- Autumn D Zuckerman
- Vanderbilt Specialty Pharmacy, Vanderbilt University Medical Center, Nashville, TN, USA
| | | | - Amy Smith
- University Specialty Pharmacy, University of Tennessee Medical Center, Knoxville, TN, USA
| | - Melissa Ortega
- Tufts Medicine Specialty Pharmacy, Tufts Medical Center, Boston, MA, USA
| | | | | | - Kimhouy Tong
- Outpatient Pharmacy Services, Yale New Haven Health, Hamden, CT, USA
| | | | - Tara Kelley
- Vanderbilt Specialty Pharmacy, Vanderbilt University Medical Center, Nashville, TN, USA
| | - Josh DeClercq
- Department of Biostatistics, Vanderbilt University Medical Center, Nashville, TN, USA
| | - Leena Choi
- Department of Biostatistics, Vanderbilt University Medical Center, Nashville, TN, USA
| | - Gabrielle Pierce
- American Society of Health-System Pharmacists, Bethesda, MD, USA
| |
Collapse
|
5
|
Moshel S, Klang S, Nikname R, Bar Shalom K, Albukrek D, Zacay G. Automated versus manual prior authorization for diabetes mellitus drugs: A retrospective study from Israel. Digit Health 2023; 9:20552076231203889. [PMID: 37780061 PMCID: PMC10540583 DOI: 10.1177/20552076231203889] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/16/2023] [Accepted: 09/08/2023] [Indexed: 10/03/2023] Open
Abstract
Introduction Drug prior authorization (PA) imposes a bureaucratic and economic burden on healthcare service providers and payers. A novel automated PA system may improve these drawbacks. Methods An historical cohort study from a large health maintenance organization in Israel, comparing manual versus automated PA mechanisms for diabetes mellitus (DM) drugs: sodium-glucose co-transporter-2 inhibitors (SGLT2i) and glucagon-like peptide-1 analogs (GLP1-A). We compared patients with DM, whose first drug applications were approved using the automated system, with similar patients whose first drug applications were approved by manual PA. The primary endpoint was the time elapsed from application approval to prescription filling (accessibility time). Secondary endpoints included the prescription filling rate at 7 and 30 days. Results In total, 1371 automated approved prescriptions and 1240 manually approved prescriptions were included in the analysis. Median accessibility time was one day (interquartile range (IQR) 0-5) with automated PA for both GLP1-A and SGLT2i, compared with four days (IQR 1-9) and three days (IQR 1-8), respectively, with the manual PA (p < 0.001). Eighty-four percent of GLP1-A automated PA approvals were filled within seven days compared with 70% with manual PA (p < 0.001). Similar results were seen with SGLT2i (80% vs. 72%, p < 0.008). No differences were observed at 30 days post-approval. Using logistic regression, odds for GLP1-A and SGLT2i prescription filling within seven days were 2.36 and 1.53 folds higher (respectively) with automated PA (p < 0.01). Conclusions Automated PA system improved access time to SGLT2i/GLP1-A seven days post-approval compared to manual PA.
Collapse
Affiliation(s)
- Shai Moshel
- Meuhedet Health Services, Tel Aviv, Israel
- Department of Health System Management, Peres Academic Center, Rehovot, Israel
| | - Shmeul Klang
- School of Public Health, University of Haifa, Haifa, Israel
| | | | | | | | - Galia Zacay
- Meuhedet Health Services, Tel Aviv, Israel
- Department of Family Medicine, Faculty of Medicine, University of Tel Aviv, Tel Aviv, Israel
| |
Collapse
|
6
|
Gabriel MH, Kotschevar CM, Tarver D, Mastrangelo V, Pezzullo L, Campbell PJ. Specialty pharmacy turnaround time impediments, facilitators, and good practices. J Manag Care Spec Pharm 2022; 28:1244-1251. [PMID: 36282928 PMCID: PMC10372971 DOI: 10.18553/jmcp.2022.28.11.1244] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/15/2023]
Abstract
BACKGROUND: Patients receiving specialty medications have conditions that are often complex, high cost, and high need. Prompt treatment initiation is essential for the appropriate management of many conditions treated by specialty products. Improving the turnaround time (TAT) of specialty pharmacy prescriptions helps ensure patients receive the medication they need in the necessary time frame to optimize health outcomes. Despite a clinical justification for improved TAT, there is a gap in the literature describing what factors impact these times. OBJECTIVE: To determine factors that may influence specialty pharmacy TATs and to identify good practices that specialty pharmacies use to improve TAT. METHODS: This qualitative study used 4 focus groups with specialty pharmacy subject matter experts. Each focus group represented different specialty pharmacy types, including health system, payer-associated, retail chain, and independent specialty pharmacies. Attitudes, beliefs, and experiences regarding specialty pharmacy TAT were captured. Open-ended questions and prompts eliciting impediments, facilitators, and good practices associated with specialty pharmacy TAT were asked of participants. Data were analyzed thematically. RESULTS: Fifteen individuals participated across 4 focus groups: payer-associated (n = 4), independent (n = 3), health system (n = 5), and retail chain (n = 3) specialty pharmacies. Average TATs varied across specialty pharmacy type and by prescription type (clean vs intervention). Several interconnected themes were identified, including barriers with health benefits formulary management, prior authorization delays, differences in requirements between managed care organizations, and miscommunication with physicians, among others. Five subthemes were identified during the discussion of factors influencing TAT, including patient characteristics, pharmacy characteristics, provider characteristics, clinical situations, and health benefit design and formulary considerations. Pharmacy workflow improvements through technology integration are thought to improve TAT. In addition, participants noted facilitators including specialization among pharmacists and technicians in certain diseases, particularly hepatitis C and cancer. Some good practices included using patient financial advocates, technology integration, and a structured patient onboarding process, which were found to minimize delays caused by prior authorization, communication, and formularies. CONCLUSIONS: A multitude of factors impacting specialty pharmacy prescription TAT were identified. Multidisciplinary coordination between pharmacies, physicians, and managed care organizations is essential to ensure patients receive medications in the necessary time frame to optimize health outcomes. DISCLOSURES: This study was conducted with support from Pfizer.
Collapse
|
7
|
Zuckerman AD, Whelchel K, Kozlicki M, Simonyan AR, Donovan JL, Gazda NP, Mourani J, Smith AM, Young L, Ortega M, Kelley TN. Health-system specialty pharmacy role and outcomes: A review of current literature. Am J Health Syst Pharm 2022; 79:1906-1918. [PMID: 35916907 DOI: 10.1093/ajhp/zxac212] [Citation(s) in RCA: 15] [Impact Index Per Article: 7.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
DISCLAIMER In an effort to expedite the publication of articles, AJHP is posting manuscripts online as soon as possible after acceptance. Accepted manuscripts have been peer-reviewed and copyedited, but are posted online before technical formatting and author proofing. These manuscripts are not the final version of record and will be replaced with the final article (formatted per AJHP style and proofed by the authors) at a later time. PURPOSE Specialty medications can have life-altering outcomes for patients with complex diseases. However, their benefit relies on appropriate treatment selection, patients' ability to afford and initiate treatment, and ongoing treatment optimization based on patient response to therapy. Mounting research demonstrates the benefits of the health-system specialty pharmacy (HSSP) in improving specialty medication access, affordability, and outcomes. The purpose of this rapid review is to describe the currently reported role and function of HSSP pharmacists and outcomes reported with use of the HSSP model, and to identify gaps in the literature where more information is needed to better understand the HSSP model and outcomes. SUMMARY Current literature describes the role of HSSP pharmacists in facilitating patient access, affordability, and initiation and maintenance of specialty medications. Though it is clear HSSP pharmacists are involved in treatment monitoring, often through utilizing the electronic health record, more information is needed to elucidate the frequency, method, and extent of monitoring. Despite several valuable continuity of care services reported to be provided by HSSPs, the breadth and degree of standardization of these services remains unclear. There is minimal literature describing HSSP education and research involvement. HSSPs have reported significant benefits of this patient care model, as demonstrated by higher adherence and persistence; better clinical outcomes; financial benefits to patients, payers and the health system; better quality of care; higher patient and provider satisfaction with services, and highly efficient specialty pharmacy services. More literature comparing clinical and diagnosis-related outcomes in HSSP versus non-HSSP patients is needed. CONCLUSION HSSPs provide comprehensive, patient-centered specialty medication management that result in improved care across the continuum of the specialty patient journey and act as a valuable resource for specialty clinics and patients beyond medication management. Future research should build on the current description of HSSP services, how services affect patient outcomes, and the impact HSSP network restrictions.
Collapse
Affiliation(s)
| | | | | | | | | | | | | | | | - Lauren Young
- University of Tennessee Medical Center, Knoxville, TN, USA
| | | | - Tara N Kelley
- Vanderbilt University Medical Center, Nashville, TN, USA
| |
Collapse
|
8
|
Zuckerman AD, DeClercq J, Choi L, Cowgill N, McCarthy K, Lounsbery B, Shah R, Kehasse A, Thomas K, Sokos L, Stutsky M, Young J, Carter J, Lach M, Wise K, Thomas TT, Ortega M, Lee J, Lewis K, Dura J, Gazda NP, Gerzenshtein L, Canfield S. Adherence to self-administered biologic disease-modifying antirheumatic drugs across health-system specialty pharmacies. Am J Health Syst Pharm 2021; 78:2142-2150. [PMID: 34407179 PMCID: PMC8385960 DOI: 10.1093/ajhp/zxab342] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/16/2022] Open
Abstract
Disclaimer In an effort to expedite the publication of articles related to the COVID-19 pandemic, AJHP is posting these manuscripts online as soon as possible after acceptance. Accepted manuscripts have been peer-reviewed and copyedited, but are posted online before technical formatting and author proofing. These manuscripts are not the final version of record and will be replaced with the final article (formatted per AJHP style and proofed by the authors) at a later time. Purpose Adherence to self-administered biologic disease-modifying antirheumatic drugs (bDMARDs) is necessary for therapeutic benefit. Health-system specialty pharmacies (HSSPs) have reported high adherence rates across several disease states; however, adherence outcomes in rheumatoid arthritis (RA) populations have not yet been established. Methods We performed a multisite retrospective cohort study including patients with RA and 3 or more documented dispenses of bDMARDs from January through December 2018. Pharmacy claims were used to calculate proportion of days covered (PDC). Electronic health records of patients with a PDC of <0.8 were reviewed to identify reasons for gaps in pharmacy claims (true nonadherence or appropriate treatment holds). Outcomes included median PDC across sites, reasons for treatment gaps in patients with a PDC of <0.8, and the impact of adjusting PDC when accounting for appropriate therapy gaps. Results There were 29,994 prescriptions for 3,530 patients across 20 sites. The patient cohort was mostly female (75%), with a median age of 55 years (interquartile range [IQR], 42-63 years). The original(ie, prereview) median PDC was 0.94 (IQR, 0.83-0.99). Upon review, 327 patients had no appropriate treatment gaps identified, 6 patients were excluded due to multiple unquantifiable appropriate gaps, and 420 patients had an adjustment in the PDC denominator due to appropriate treatment gaps (43 instances of days’ supply adjusted based on discordant days’ supply information between prescriptions and physician administration instructions, 11 instances of missing fills added, and 421 instances of clinically appropriate treatment gaps). The final median PDC after accounting for appropriate gaps in therapy was 0.95 (IQR, 0.87-0.99). Conclusion This large, multisite retrospective cohort study was the first to demonstrate adherence rates across several HSSPs and provided novel insights into rates and reasons for appropriate gaps in therapy.
Collapse
Affiliation(s)
| | - Josh DeClercq
- Department of Biostatistics, Vanderbilt University Medical Center, Nashville, TN, USA
| | - Leena Choi
- Department of Biostatistics, Vanderbilt University Medical Center, Nashville, TN, USA
| | - Nicole Cowgill
- CHS Specialty Pharmacy Service at Atrium Health, Charlotte, NC, USA
| | - Kate McCarthy
- Specialty Pharmacy, University of Rochester Medical Center, Rochester, NY, USA
| | | | - Rushabh Shah
- UK Specialty Pharmacy and Infusion Services, University of Kentucky, Lexington, KY, USA
| | | | - Karen Thomas
- Pharmacy Ambulatory Clinical Care Center, University of Utah Health, Salt Lake City, UT, USA
| | - Louis Sokos
- West Virginia University Health System, Morgantown, WV, USA
| | - Martha Stutsky
- Specialty and Retail Pharmacy Services, Yale New Haven Health System, New Haven, CT, USA
| | - Jennifer Young
- Specialty Pharmacy Services, Wake Forest Baptist Health, Winston-Salem, NC, USA
| | | | - Monika Lach
- University of Chicago Medicine, Chicago, IL, USA
| | - Kelly Wise
- Nationwide Children's Hospital, Columbus, OH, USA
| | - Toby T Thomas
- Hospital of the University of Pennsylvania, Philadelphia, PA, USA
| | | | - Jinkyu Lee
- Beth Israel Deaconess Medical Center, Boston, MA, USA
| | - Kate Lewis
- Froedtert & the Medical College of Wisconsin, Milwaukee, WI, USA
| | | | | | | | | |
Collapse
|
9
|
Stubbings J, Pedersen CA, Low K, Chen D. ASHP National Survey of Health-System Specialty Pharmacy Practice-2020. Am J Health Syst Pharm 2021; 78:1765-1791. [PMID: 34345889 DOI: 10.1093/ajhp/zxab277] [Citation(s) in RCA: 17] [Impact Index Per Article: 5.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/19/2022] Open
Abstract
PURPOSE Results of the first ASHP National Survey of Health-System Specialty Pharmacy Practice are presented. METHODS A sample of 230 leaders in health-system specialty pharmacies were contacted by email and invited to participate in a survey hosted using an online survey application. The survey sample was compiled from ASHP member lists, through review of data from other ASHP surveys indicating the presence of specialty pharmacies, and by outreach to ASHP member organizational leaders. RESULTS The response rate was 53.0%. Most health-system specialty pharmacies dispense 30,000 or fewer specialty prescriptions per year, have an annual revenue of $100 million or less, are part of an entity eligible to participate in the 340B Drug Pricing Program, operate 1 specialty pharmacy location, have at least 1 specialty pharmacy accreditation, dispense nonspecialty medications in addition to specialty medications, and employ an average of 13 pharmacists and 15 technicians. More than two-thirds of health-system specialty pharmacies (68.8%) dispense no more than half of the prescriptions written by their providers due to payer network restrictions or limited distribution drugs. The health-system specialty pharmacy practice model includes access to the electronic health record (100% of respondents), pharmacists and technicians dedicated to specific clinics (64.9% and 57.7%, respectively), specialty pharmacist involvement in treatment decisions and drug therapy selection prior to the prescription being written (64.9%), and documenting recommendations and progress notes in patients' electronic health record (93.4%). Most health-system specialty pharmacies (83.3%) offer experiential or formal education in specialty pharmacy. Top challenges that survey respondents expected to face in the next year included restricted access to payer networks and limited distribution drugs, 340B Drug Pricing Program changes, and shrinking reimbursement from payers. CONCLUSION The health-system specialty pharmacy represents an integrated advanced practice model that incorporates specialty medication-use management across the continuum of care.
Collapse
Affiliation(s)
- JoAnn Stubbings
- Department of Pharmacy Practice, University of Illinois Chicago College of Pharmacy, Chicago, IL, USA
| | - Craig A Pedersen
- Virginia Mason Medical Center, Seattle, WA.,University of Washington, Seattle, WA, USA
| | - Karly Low
- American Society of Health-System Pharmacists, Bethesda, MD, USA
| | - David Chen
- American Society of Health-System Pharmacists, Bethesda, MD, USA
| |
Collapse
|